%0 Journal Article
%T 含奥沙利铂方案与FOLFIRI方案一线化疗对K-ras基因不同状态晚期大肠癌患者的疗效及预后影响比较
%A 姜鹤群
%A 张杰
%A 徐可
%A 王少龙
%J 肿瘤防治研究
%D 2015
%R 10.3971/j.issn.1000-8578.2015.03.015
%X 摘要 目的 探究含奥沙利铂方案与FOLFIRI方案对Ⅳ期结直肠癌化疗疗效及预后影响的差别与K-ras基因状态的关系。方法 收集2010年1月至2012年1月的118例接受含奥沙利铂方案或FOLFIRI方案化疗的Ⅳ期结直肠癌患者临床资料，统计患者的治疗有效率（ORR）、疾病控制率（DCR）、无进展生存时间（PFS）和总生存期（OS）。采用χ2检验比较各组临床因素差别和两种治疗方案的有效率及疾病控制率，采用Kaplan-Meier法比较无进展生存时间以及总生存期。结果 118例患者中，接受含奥沙利铂方案化疗的K-ras突变型患者PFS及OS较接受FOLFIRI方案化疗患者延长（P=0.048；P=0.037），ORR及DCR较接受FOLFIRI方案化疗患者无明显差别（P=0.961；P=0.931）。接受含奥沙利铂方案化疗的K-ras野生型患者ORR、DCR、PFS及OS较接受FOLFIRI方案化疗患者无明显差别（P=0.900；P=0.802；P=0.738；P=0.904）。结论 采用含奥沙利铂方案一线化疗较FOLFIRI方案对K-ras突变型Ⅳ期结直肠癌患者更有优势，而对于K-ras野生型Ⅳ期结直肠癌患者，含奥沙利铂方案与FOLFIRI方案疗效及预后情况相当
%K A Meta-analysis
%K UGCG is Involved in Oxaliplatin Resistance Mechanism of Human Colon Cancer Through Regulating MDR1/P-gp Expression
%K Chemotherapy Promotes Mesenchymal Stem Cells Homing by Enhancing Cytokine Receptors Expression on Tumor Cells
%K Clinical Investigation on Qingfei Mixture Combined with Chemotherapy on Middle and Advanced Non-small Cell Lung Cancer
%K Predictive Factors for Customizing Chemotherapy on Advanced Lung Adenocarcinoma
%K Differences of Clinical Features and Short-term Efficacy Between Diffuse Large B-cell Lymphomas of HIV-infected and Non-HIV-infected Patients
%K Efficacy and Safety of Weekly Liposome-paclitaxel or Oxaliplatin Combined with Tegafur on Elderly Advanced Gastric Cancer
%K Risk Factors Associated with Hematologic Toxicity in Concurrent Chemoradiotherapy and IMRT for Cervical Cancer
%K Clinical Investigation on Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy on Patients with Peritoneal Carcinomatosis from Epithelial Ovarian Cancer
%U http://www.zlfzyj.com/CN/abstract/abstract8448.shtml